FMC and Corteva Partner to Expand Access to Fluindapyr Fungicide

FMC Corporation (FMC) has partnered with Corteva Agriscience to expand the reach of its fluindapyr fungicide in the U.S. corn and soybean markets, with Corteva planning to launch a fluindapyr-based product by the 2026 growing season, pending EPA approval. This collaboration aims to provide more farmers access to advanced solutions for managing foliar diseases across roughly 175 million acres of planted land. Despite this partnership, FMC maintained its 2025 revenue outlook at $4.15-$4.35 billion and adjusted EBITDA forecast at $870-$950 million, while the company's shares have underperformed, declining 29.7% in the last six months.

Analysis

FMC Corporation has entered into a strategic partnership with Corteva Agriscience to expand the market reach of its fluindapyr fungicide technology within the U.S. corn and soybean sectors, which collectively represent approximately 175 million planted acres. Under this agreement, Corteva plans to launch its fluindapyr-based product by the 2026 growing season, contingent upon Environmental Protection Agency (EPA) registration, while FMC will continue marketing its Adastrio fungicide and developing new fluindapyr products. This collaboration is designed to provide American farmers with enhanced solutions for challenging foliar diseases like tar spot and southern rust, leveraging fluindapyr's long-lasting residual control and efficacy against resistant pathogens. Despite this strategic initiative aimed at future growth, FMC's stock has significantly underperformed, declining 29.7% over the past six months compared to a 1.2% decline for the industry. The company has maintained its 2025 financial outlook, projecting revenues between $4.15-$4.35 billion (flat year-over-year at the midpoint), adjusted EBITDA of $870-$950 million (a 1% increase at midpoint, or 4% excluding the GSS divestiture impact), and adjusted earnings per share of $3.26-$3.70 (flat at midpoint). This guidance incorporates an estimated $15-$20 million in incremental tariff costs, and the company's current Zacks Rank is #3 (Hold), reflecting a mixed near-term view despite the positive long-term implications of the partnership.

Key Decisions for Investors

• Investors should consider the long-term strategic value of the Corteva partnership in potentially expanding fluindapyr's market share and revenue contribution post-2026, but must weigh this against FMC's flat financial guidance for 2025 and its significant recent share price underperformance.
• Closely monitor the progress of EPA registration for Corteva's fluindapyr-based product and its subsequent market adoption following the planned 2026 launch, as these are critical milestones for realizing the partnership's anticipated benefits.
• Evaluate whether FMC's current depressed stock valuation adequately reflects the maintained, albeit uninspiring, 2025 outlook, the impact of incremental tariff costs, and the future growth opportunities from the fluindapyr expansion, particularly in light of its Zacks #3 (Hold) rating.